
    
      The drug being tested in this study is ixazomib. Ixazomib is being tested to treat people who
      have multiple myeloma. This study will look at the safety and efficacy of ixazomib and will
      enroll approximately 60 participants.

      Participants will receive ixazomib by oral capsule twice weekly on Days 1, 4, 8, and 11 of a
      21-day cycle. The study will consist of a dose escalation phase to determine the MTD,
      followed by an expansion phase in which participants will be treated at the MTD.

      This multi-center trial will be conducted in the United States. The overall time to
      participate in this study is 8 years.
    
  